Lynoo Pharmaceutical Packaging nine-month profit falls 19% after Hong Kong listing filing

Shenzhen-listed Lynoo Pharmaceutical Packaging reported nine-month 2026 revenue up 38.78% to USD 150.5m (RMB 1.001bn). Net profit attributable to shareholders fell 19.03% to USD 6.19m (RMB 41.2m), and operating cash flow was an outflow of USD 7.8m (RMB 51.9m). Short-term borrowings rose 358.57% from end-2025. The company applied for a Hong Kong H-share listing on 28 September 2026. Proceeds are partly intended for ready-to-use packaging and pre-fillable syringes, and for a semiconductor glass substrate business that has no revenue or orders yet.

Why this mattersChina's ninth-largest pharma glass packager is raising capital abroad while profit and cash flow weaken, with proceeds partly funding a glass substrate line that has no orders yet.

• Nine-month 2026 revenue USD 150.5m (RMB 1.001bn), up 38.78% year on year
• Net profit attributable to parent USD 6.19m (RMB 41.2m), down 19.03%
• Net operating cash outflow of USD 7.8m (RMB 51.9m) for the period
• Short-term borrowings up 358.57% from end-2025
• H-share listing application submitted to HKEX on 28 September 2026
• Ranked ninth in China's pharmaceutical glass packaging market in 2025 with a 2.4% share

Relevant to you? Yes No